Good morning, everyone, and nice to see you again. We took an extended weekend respite to spend time with some of our short people, but now the sojourn has sadly come to an end. Perhaps you can relate. In any event, we hope your own break was relaxing, because the usual routine of meetings, deadlines and whatnot has now returned. To cope, yes, we are quaffing cups of stimulation and invite you to do the same. Meanwhile, here are some tidbits. Have a smashing and do keep in touch …
AstraZeneca is considering an offer for Medivation, which recently rejected a bid from Sanofi, the Telegraph reports. Medivation, which is valued at $8.7 billion, hired JP Morgan to help defend itself from an unwanted takeover. The company is generating interest from other drug makers thanks to its Xtandi prostate cancer treatment. Earlier this year, AstraZeneca ruled out large deals unless they could immediately boost earnings.
Manufacturers of biosimilars have teamed up to win acceptance in the UK for their medicines from doctors and patients, the Financial Times reports. The British Biosimilars Association arrives as the National Health Service faces financial stress over the cost of medicines. Expensive biologics drugs account for six of the top 10 medicine expenditures by the NHS.
About the Author Reprints
In blog Milliman’s Scott Weltz discusses the factors contributing to the high cost of prescription drugs. Review more: http://www.healthcaretownhall.com/?p=7761